Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have a solid tumour cancer that has spread or cannot be surgically removed, and whose cancer has continued to grow or worsened after receiving at least one prior treatment
- People whose tumour tissue or blood tests show one or more specific gene changes (called PIK3CA mutations) that are known to drive cancer growth
- People who have at least one area of cancer that can be measured or assessed using standard imaging methods
- People who are in good enough general health to carry out everyday activities with no or only minor limitations (this is measured using a standard scale called ECOG, with a score of 0 or 1)
- People whose organs (such as the liver, kidneys, and bone marrow) are functioning at an adequate level
Who may not be able to join:
- People who have diabetes and require medication to control their blood sugar levels
- People who have previously been treated with a specific class of cancer drugs called PI3Kα inhibitors
- People who have cancer that has spread to the brain or spinal cord and is currently causing symptoms, has not been treated, or is not well controlled
- People who have received any cancer treatment — including experimental treatments — within a specific period of time before the study begins (confirm with trial site for exact timeframes)
- People who still have significant side effects from a previous cancer treatment that have not yet resolved
- People who have been diagnosed with a second, separate cancer within the past two years, unless that cancer has been fully and adequately treated (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 857-331-3898
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose limiting toxicities (DLTs); Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.